Abstract
The “Endocannabinoid System” (ECS) was not discovered until early in the 1990s, as a result of research to understand the actions of Δ9-THC (THC) on the nervous system. Some of this work determined that THC works by binding to two endogenous membrane receptors that had not been identified prior. These endogenous membrane receptors were identified as G-protein coupled receptors (GPCR) and named Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2). After the discovery of these receptors, it was a short path to find the endogenous ligands that pair with these receptors (Panagis et al. 2014).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abramovici, H., Lamour, S. A., & Mammen, G. (2018). Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids. Health Canada Publication. ISBN: 978-0-660-27828-5.
Camilleri, M., Kolar, G. J., Vazquez-Roque, M. I., Carlson, P., Burton, D. D., & Zinsmeister, A. R. (2013). Cannabinoid receptor 1 gene and irritable bowel syndrome: Phenotype and quantitative traits. American Journal of Physiology. Gastrointestinal and Liver Physiology, 304, G553–G560.
Campora, L., Miragliotta, V., Ricci, E., Cristino, L., Di Marzo, V., Albanese, F., Frederica della Valle, M., & Abramo, F. (2012). Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. American Journal of Veterinary Research, 73, 988–995.
Chiocchetti, R., Galiazzo, G., Tagliavia, C., Stanzani, A., Giancola, F., Menchetti, M., Militerno, G., Bernardini, C., Forni, M., & Mandrioli, L. (2019). Cellular distribution of canonical and putative cannabinoid receptors in canine cervical dorsal root ganglia. Frontiers in Veterinary Science, 6, 313. https://doi.org/10.3389/fvets.2019.00313.
Dall’Aglio, C., Mercati, F., Pascucci, L., Boiti, C., Pedini, V., & Ceccarelli, P. (2010). Immunohistochemical localization of CB1 receptor in canine salivary glands. Veterinary Research Communications, 34, 9–12.
De Petrocellis, L., Melck, D., Bisogno, T., Milone, A., & Di Marzo, V. (1999). Finding of the endocannabinoid signaling system in Hydra, a very primitive organism: Possible role in the feeding response. Neuroscience, 92, 377–387.
Deutsch, D. G. (2016). A personal retrospective: Elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Frontiers in Pharmacology, 7, 370. https://doi.org/10.3389/fphar.2016.00370.
Dewey, W. L., Jenkins, J., O’Rourke, T., & Harris, L. S. (1972). The effects of chronic administration of trans-Δ9-tetrahydrocannabinol on behavior and the cardiovascular system of dogs. Archives Internationales de Pharmacodynamie et de Therapie, 198, 118–131.
Dixon, W. E. (1899). The Pharmacology of Cannabis indica. British Medical Journal, 2, 1354–1357.
Elmes, M. W., Kaczocha, M., Berger, W. T., Leung, K., Ralph, B. P., Wang, L., Sweeney, J. M., Jeremy, T., Miyauchi, J. T., Tsirka, S. E., Ojima, I., & Deutsch, D. G. (2015). Fatty acid-binding protein (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Journal of Biological Chemistry, 290, 8711–8721.
Elmes, M. W., Prentis, L. E., McGoldrick, L. L., Giuliano, C. J., Sweeney, J. M., Joseph, O. M., Joyce Che, J., Carbonetti, G. S., Studholme, K., Dale, G., Deutsch, D. G., Rizzo, R. C., Glynn, S. E., & Kaczocha, M. (2019). FABP1 controls hepatic transport and biotransformation of Delta-9-THC. Nature.com/Scientific Reports, 9, 7588.
Elphick, M. R. (2012). The evolution and comparative neurobiology of endocannabinoid signaling. Philosophical Transactions of the Royal Society B, 367, 3201–3215.
Fernandez-Trapero, M., Espejo-Porras, F., Rodriguez-Cueto, C., Coates, J. R., Perez-Diaz, C., deLago, E., & Fernandez-Ruiz, J. (2017). Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Disease Models and Mechanisms, 10, 551–558. https://doi.org/10.1242/dmm.028373.
Galiazzo, G., Giancola, F., Stanzani, A., Fracassi, F., Bernardini, C., Forni, M., Pietra, M., & Chiocchetti, R. (2018). Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract. Histochemistry and Cell Biology, 150, 187–205. https://doi.org/10.1007/s00418-018-1684-7.
Gardner, F. (2013). Mechoulam’s to-do list for researchers: CBD, the CB2 Receptor, and ‘F-Triple-A’s’. O’Shaughnessy’s, Winter/Spring, 7–9.
Griffin, G., Wray, E. J., Tao, Q., McAllister, S. D., Rorrer, W. K., Aung, M., Martin, B. R., & Abood, M. E. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: Further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. European Journal of Pharmacology, 377, 117–125.
Heitland, I., Klumpers, F., Oosting, R. S., Evers, D. J. J., Kenemansa, L. J., & Baas, J. M. P. (2012). Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. Translational Psychiatry, 2, e162.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1930). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America, 87, 1932–1936.
Hill, M. N., McLaughlin, R. J., Morrish, A. C., Viau, V., Floresco, S. B., Hillard, C. J., & Gorzalka, B. B. (2009). Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology, 34, 2733.
Ho, B., Uezono, Y., Takada, S., Takase, I., & Izumi, F. (1999). Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors and Channels, 6, 363–374.
Howlett, A. C., Reggio, P. H., Childers, S. R., Hampson, R. E., Ulloa, N. M., & Deutsch, D. (2011). Endocannabinoid tone versus constitutive activity of cannabinoid receptors. British Journal of Pharmacology, 163, 1329–1343. https://doi.org/10.1111/j.1476-5381.2011.01364x.
Lafourcade, M., Larrieu, T., Mato, S., Duffaud, A., Sepers, M., Matias, I., De Smedt-Peyrusee, V., Labrousse, V. F., Bretillon, L., Matute, C., et al. (2011). Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nature Neuroscience, 14, 345–350.
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkotter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94.
Lu, H.C., Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. Journal of Psychiatric Neuroscience and Therapeutics. 79(7), 516-525
Mackie, K. (2008). Cannabinoid receptors: Where they are and what they do. Journal of Neuroendocrinology, 20, 10–14.
Matias, I., McPartland, J. M., & DiMarzo, V. (2005). Occurrence and possible biological role of the endocannabinoid system in the sea squirt Ciona intestinalis. Journal of Neurochemistry, 93, 1141–1156. https://doi.org/10.1111/j.1471-4159.2005.03103.
McPartland, J., Marzo, V. D., Petrocellis, L. D., Mercer, A., & Glass, M. (2001). Cannabinoid receptors are absent in insects. The Journal of Comparative Neurology, 436, 423–429.
McPartland, J. M., Agraval, J., Glesson, D., Heasman, K., & Glass, M. (2006). Cannabinoid receptors in invertebrates. Journal of Evolutionary Biology, 19, 366–373.
Mechoulam, R., Hanus, L. O., Pertwee, R., & Howlett, A. C. (2014). Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Reviews Neuroscience, 15, 757–764.
Mercati, F., Dall’Aglio, C., Pascucci, L., Boiti, C., & Ceccarelli, P. (2012). Identification of cannabinoid type 1 receptor in dog hair follicles. Acta Histochemica, 114, 68–71.
Miller, M. (2017). Localization and quantification of cannabinoid receptors in canine tissue. Proceedings of American College of Veterinary Internal Medicine.
Miragliotta, V., Ricci, P. L., Albanese, F., Pirone, A., Tognotti, D., & Abramo, F. (2018). Cannabinoid receptor types 1 and 2 and peroxisome proliferatoractivated receptor-α: Distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis. Veterinary Dermatology, 29(4), 316–e111.
Ndong, C., O’donnell, D., Ahmad, S., & Groblewski, T. (2011). Cloning and pharmacological characterization of the dog cannabinoid CB2 receptor. European Journal of Pharmacology, 669, 24–31.
Ngo, R. (2019). The endocannabinoidome: Expanding the approach to treating traumatic brain injury using the endocannabinoid system. University of Saskatchewan Undergraduate Research Journal, 5(2), 1–10. Accessed April 22, 2020, from https://usurj.journals.usask.ca/article/download/407/238/
Pacher, P., Batkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389–462.
Panagis, G., Mackey, B., & Vlachou, S. (2014 July). Cannabinoid regulation of brain reward processing with an emphasis on the role of CB1 receptors: a step back into the future. Frontiers in Psychiatry, 5(92), 1–20. https://doi.org/10.3389/psyt.2014.00092.
Papagianni, E. P., & Stevenson, C. W. (2019). Cannabinoid regulation of fear and anxiety: An update. Current Psychiatry Reports, 21, 38.
Pirone, A., Lenzi, C., Coli, A., Giannessi, E., Stornelli, M. R., & Miragliotta, V. (2015). Preferential epithelial expression of type-1 cannabinoid receptor (CB1R) in the developing canine embryo. Springerplus, 4, 804.
Pirone, A., Cantile, C., Miragliotta, V., Lenzi, C., Giannessi, E., & Cozzi, B. (2016). Immunohistochemical distribution of the cannabinoid receptor 1 and fatty acid amide hydrolase in the dog claustrum. Journal of Chemical Neuroanatomy, 74, 21–27. https://doi.org/10.1016/j.jchemneu.2016.02.002.
Pirone, A., Lenzi, C., Briganti, A., Abbate, F., Levanti, M., Abramo, F., & Miragliotta, V. (2017). Spatial distribution of cannabinoid receptor 1 and fatty acid amide hydrolase in the cat ovary and oviduct. Acta Histochemica. https://doi.org/10.1016/j.acthis.2017.04.007.
Russo, E. B. (2004). Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinology Letters, 25(1/2), 31–39.
Russo, E. B. (2016a). Beyond cannabis: Plants and the endocannabinoid system. Trends in Pharmacological Sciences, 37, 594–605.
Russo, E. B. (2016b). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1, 154–165.
Smith, D. R., Stanley, C., Foss, T., Boles, R. G., & McKernin, K. (2017). Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. PLoS One, 12, e0187926.
Veilleux, A., Di Marzo, V., & Silvestri, C. (2019). The expanded endocannabinoid system/endocannabinoidome as a potential target for treating diabetes mellitus. Current Diabetes Reports, 19(11), 117.
Zou, S., Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences, 19(3), 833.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Silver, R. (2021). The Endocannabinoid System and Endocannabinoidome. In: Cital, S., Kramer, K., Hughston, L., Gaynor, J.S. (eds) Cannabis Therapy in Veterinary Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-68317-7_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-68317-7_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-68316-0
Online ISBN: 978-3-030-68317-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)